Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
881-900 of 2,251 trials

Septic Shock: Early Use of Vasopressin

We are studying whether starting vasopressin treatment earlier helps improve kidney function in patients with septic shock. This trial aims to see if it reduces the need for kidney support and other complications in the ICU.

Septic Shock1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineNephrologyPulmonology

Lung Cancer: Repotrectinib for Elderly Patients

We are studying the effectiveness of Repotrectinib in frail or elderly patients with advanced lung cancer. The trial aims to see if this treatment can improve tumor response and overall health.

Stage III/IV Non-Small-Cell Lung Cancer with ROS1 Rearrangement>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteOncologyPulmonology

Metastatic Uveal Melanoma: Tebentafusp Treatment

We are studying the effects of tebentafusp in patients with metastatic uveal melanoma that has spread to the liver. The goal is to see if it can help achieve complete responses and improve disease control.

Uveal Melanoma>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesOncology

Ovarian Stimulation for Poor Responders: CFA vs. Modified Natural Cycles

We are comparing a single cycle of a new medication with multiple natural cycles in women who may not respond well to fertility treatments. The goal is to see which method leads to better quality embryos and higher chances of pregnancy.

Subfertility3-6 monthsMonitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesEndocrinologyGynecology and Obstetrics

Crohn's Disease: New Treatment Target Study

We are investigating if aiming for complete healing of all bowel layers improves outcomes for patients with active Crohn's disease. This study compares different treatment strategies to see which is more effective.

Crohn's Disease1-2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesGastroenterologyInternal Medicine

TMJ Arthritis: Cortisone Injection vs. Arthrocentesis

We are comparing the effectiveness of a cortisone injection and a procedure called arthrocentesis for relieving pain in people with TMJ arthritis. We also want to see how these treatments affect mouth opening and if other factors play a role in recovery.

Temporomandibular Joint Arthritis3-6 monthsMonitoring phase (IV)No PlaceboStandard MedicinesOrthopedics and Traumatology

Primary Immune Thrombocytopenia: Belantamab Mafodotin Study

We are investigating a new treatment for adults with primary immune thrombocytopenia who have previously received other therapies. The study aims to assess the safety and effectiveness of this new drug.

Primary Immune Thrombocytopenia1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesHematology

Pulmonary Arterial Hypertension: Sotatercept Study

We are evaluating the long-term safety of sotatercept for adults with pulmonary arterial hypertension already on treatment. This study will help us understand how well it works when added to existing therapies.

Pulmonary Arterial Hypertension>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteCardiology

Advanced Solid Tumors: TransCon IL-2 β/γ Treatment Study

We are investigating the safety and tolerability of TransCon IL-2 β/γ alone and with other cancer therapies for adults with advanced solid tumors. This study aims to find the best dose and understand how it works in combination with existing treatments.

Advanced Solid Tumor Cancers>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Systemic Lupus Erythematosus: Belimumab Study

We are studying the effects of belimumab in adults with early systemic lupus erythematosus to see if it helps improve their condition and reduce steroid use.

Systemic Lupus Erythematosus>2 yearsMonitoring phase (IV)16-20 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteRheumatology

Targeted Anti-Cancer Drugs: DRUP Trial

We are studying how well existing targeted drugs work for patients with advanced cancers that have specific genetic markers. This trial aims to improve access to effective treatments and gather important data on their use.

Non-Hodgkin LymphomaAdvanced Solid TumorT-cell Prolymphocytic Leukemia3-6 monthsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Kidney Function: Non-Radioactive Measurement Methods

We are evaluating a new non-radioactive method for measuring kidney function in comparison to traditional radioactive techniques. This study aims to ensure accurate assessments while minimizing radiation exposure.

Chronic Kidney Disease3-6 monthsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementInternal MedicineNephrology

Extrahepatic Cholangiocarcinoma: Durvalumab with Radiofrequency Ablation

We are studying a new treatment combining durvalumab and radiofrequency ablation for patients with bile duct cancer. The goal is to see if this combination improves effectiveness and safety compared to standard therapies.

Extrahepatic Cholangiocarcinoma>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

Avian Influenza Vaccine: Immune Response Study

We are studying how well a new avian influenza vaccine triggers immune responses in people, especially those with prior seasonal flu vaccinations. This research aims to understand its effectiveness against various H5N1 virus strains.

Avian Influenza and Seasonal Influenza1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesInfectious DiseasesPulmonology

Kidney Function: Vonafexor Study

We are studying the effects of vonafexor on kidney function in people with impaired renal function and suspected MASH. The trial will help us understand how different doses impact kidney health and safety.

Impaired Renal Function and Suspected MASH6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesEndocrinologyNephrology

BRAF-V600E Mutant Metastatic Colorectal Cancer: BRAVE Trial

We are studying a combination of encorafenib, cetuximab, and bevacizumab for patients with BRAF-V600E mutated metastatic colorectal cancer who have not responded to previous treatments. The trial aims to evaluate the safety and effectiveness of this treatment approach.

Metastatic Colorectal Cancer6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesOncology

Acute Myeloid Leukemia: CD19 CAR-T Cell Therapy

We are studying the safety of a new CAR-T cell treatment for patients with refractory acute myeloid leukemia. This trial aims to see how well the treatment works and how long the CAR-T cells last in the body.

Recurrent Acute Myeloid Leukemia>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Fast-Acting Insulins and Their Post-Meal Effects in Type 1 Diabetes

We are studying how different fast-acting insulins affect blood sugar levels after meals in people with type 1 diabetes. This research may help identify the best insulin for managing glucose and reducing oxidative stress.

Type 1 Diabetes1-2 yearsSafety phase (I)No PlaceboStandard MedicinesDiabetologyEndocrinology

Cytisine vs. Nicotine Replacement Therapy for Smokers with Chronic Kidney Disease

We are studying whether cytisine can help nicotine-dependent patients with chronic kidney disease quit smoking more effectively than traditional nicotine replacement therapy. This trial will also look at any side effects from both treatments.

Nicotine DependenceChronic Kidney DiseaseMonitoring phase (IV)No PlaceboStandard MedicinesNephrologyPsychiatry

Ulcerative Colitis in Kids: Ozanimod Study

We are testing the oral medication ozanimod in children with moderately to severely active ulcerative colitis who haven't responded to other treatments. The goal is to see if it helps improve their symptoms and overall health.

Ulcerative Colitis1-2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyPediatrics